These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4968248)

  • 21. [Comparative study of thiotepa, adriamycin and cisplatin in the prophylaxis of recurrence of superficial bladder carcinoma in a group of 217 patients].
    Llopis B; Gallego J; Boronat F; Moreno B; Mompó JA; Jiménez JF
    Actas Urol Esp; 1986; 10(4):225-30. PubMed ID: 3092589
    [No Abstract]   [Full Text] [Related]  

  • 22. [Preventive value of intravesical thiotepa on the recurrence of Ta-T1 vesical tumors treated by conservative surgery. Apropos of 247 cases a mean follow-up of 88 months].
    Gilloz A; Sauvage I; Gremillet E; Héritier P; Richard A; el Hajj E; Diez-Yanguas J
    J Urol (Paris); 1987; 93(4):197-202. PubMed ID: 3119728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
    Flanigan RC; Ellison MF; Butler KM; Gomella LG; McRoberts JW
    J Urol; 1986 Jul; 136(1):35-7. PubMed ID: 3086575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Local administration of thio-tepa in the prevention of papillomatous neoplasms of the urinary bladder].
    Kaczmarek A
    Wiad Lek; 1977 Feb; 30(3):187-91. PubMed ID: 402747
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder.
    Pan JS; Slocum HK; Rustum YM; Greco WR; Gaeta JF; Huben RP
    J Urol; 1989 Dec; 142(6):1589-93. PubMed ID: 2511340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa.
    Prout GR; Koontz WW; Coombs LJ; Hawkins IR; Friedell GH
    J Urol; 1983 Oct; 130(4):677-80. PubMed ID: 6411939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Superficial bladder cancer: prophylaxis of recurrence and progression].
    Miyanaga N; Akaza H; Koiso K
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2369-74. PubMed ID: 1719939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Local chemotherapy of bladder epitheliomas].
    Martinez-Piñeiro JA
    Acta Oncol (Madr); 1970; 9(1):1-27. PubMed ID: 4990619
    [No Abstract]   [Full Text] [Related]  

  • 29. Prophylactic effect of triethylenethiophosphoramide on the recurrence rate of superficial bladder tumors.
    Mukamel E; Zitron S; Nissenkorn I; Servadio C
    Isr J Med Sci; 1980; 16(9-10):714-6. PubMed ID: 6776072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adrianycin as intracavitary coadjuvant treatment of superficial bladder tumors. Our initial experiences].
    Martínez Lasierra M; Caro Cebrián C; Sanz Vélez JI; Roncalés A; Rioja Sanz C
    Actas Urol Esp; 1981; 5(4):219-22. PubMed ID: 6797270
    [No Abstract]   [Full Text] [Related]  

  • 31. [Thio-tepa in the prevention of recurrences of papillary bladder tumors].
    Kierfeld G; Mellin P
    Z Urol Nephrol; 1973 Aug; 66(8):569-72. PubMed ID: 4204011
    [No Abstract]   [Full Text] [Related]  

  • 32. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H; Benson RC; Hilton JF; Taylor WF
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Directed chemotherapy in superficial carcinoma of the bladder conditioned by the knowledge of recurrence factors].
    Oliver F; Llopis B; Vera C; Domínguez C; Vidal J; Gallego J; Jiménez JF
    Actas Urol Esp; 1989; 13(1):41-3. PubMed ID: 2496584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
    Wang SH
    Zhonghua Wai Ke Za Zhi; 1992 Jul; 30(7):410-2, 443-4. PubMed ID: 1301342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy for bladder cancer.
    Veenema RJ; Romas NA; Fingerhut B
    Urology; 1974 Feb; 3(2):135-9. PubMed ID: 4204755
    [No Abstract]   [Full Text] [Related]  

  • 36. Chemotherapy in superficial neoplasms of the bladder.
    Zingg E; Sulmoni A
    S Afr Med J; 1972 Jul; 46(27):916-7. PubMed ID: 4626807
    [No Abstract]   [Full Text] [Related]  

  • 37. [Chemoprophylaxis with intravesical thiotepa in non-infiltrating bladder tumors].
    Lancina Martín J; Monsalve Rodríguez M; Gómez Cisneros S; García Alonso J
    Arch Esp Urol; 1986 Sep; 39(7):479-83. PubMed ID: 3099658
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemoprophylaxis of bladder cancer recurrence: immunological aspects.
    Corrado F; Lalanne G; Pizza GC
    Panminerva Med; 1974 Mar; 16(3):85-91. PubMed ID: 4217438
    [No Abstract]   [Full Text] [Related]  

  • 39. Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
    Faraj K; Chang YH; Rose KM; Habermann EB; Etzioni DA; Blodgett G; Castle EP; Humphreys MR; Tyson Ii MD
    Can J Urol; 2019 Oct; 26(5):9922-9930. PubMed ID: 31629441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic treatment for superficial bladder cancer following transurethral resection.
    Hirao Y; Okajima E; Ohara S; Ozono S; Hiramatsu T; Yoshida K; Yamada K; Aoyama H; Hashimoto M; Watanabe S
    Cancer Chemother Pharmacol; 1987; 20 Suppl():S85-90. PubMed ID: 3117402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.